Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK112 in unresectable hepatocellular carcinoma
CTR20221577Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoints: Safety and Objective response rate. Started Aug 2022; status: completed.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221577.